Tag: TNBC

Triple-negative breast cancer (TNBC) remains one of the most challenging and most malignant subtypes of breast cancer to treat. TNBC represents a heterogeneous group...

ESMO 2025: Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care

ESMO 2025: First Global Phase I Results of Izalontamab Brengitecan in Patients with Advanced Solid Tumors

A first patients has been dosed in the WIN-B study (NCT06612203)*, a Phase 1b/2, multi-center investigator-initiated trial evaluating the safety and preliminary efficacy of...

German-based Tubulis continues the expansion of its clinical pipeline with a second ADC drug candidate entering the clinic. Earlier this week the company announced the dosing of the first patient in the 5-STAR-1-01 clinical trial evaluating ADC candidate TUB-030 in solid tumors.

Updated results from the BEGONIA phase 1b/2 trial for the cohort of patients treated with datopotamab deruxtecan + durvalumab (Imfinzi®; AstraZeneca;  Arm 7) showed that the treatment combination demonstrated durable tumor responses without  new safety signals in patients with previously untreated advanced or metastatic triple negative breast cancer (mTNBC) with six months additional follow-up from the previous data cut-off.

This week the U.S. Food and Drug Administration (FDA) has granted full approval to Sacituzumab Govitecan* (Trodelvy®; Gilead Sciences) for the treatment of adult...

China-based Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative products, address critical unmet medical needs for patients in Greater China and...

Privately-owned Swiss biotech company NBE-Therapeutics confirmed closing of a US $ 22M Series C financing round. The financing round was led by its existing...

Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...